Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of sickle cell gene therapy ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts ...

Cell and gene therapy manufacturers that adopt automated bioprocessing technologies are likely to use AI in QA/QC and batch release.

To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to ...

Investigators have developed STITCHR, a new gene editing tool that can insert therapeutic genes into specific locations without causing unwanted mutations. The system can be formulated completely as ...

Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...

Gene therapy for cystic fibrosis is advancing fast. Explore key biotech players, clinical progress, and its potential to ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...

The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.